Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-muscle myosin heavy chain IIA (NMHC IIA), encoded by the MYH9 gene, is a key subunit of non-muscle myosin IIA (NM IIA), an actin-based molecular motor that utilizes ATP hydrolysis to generate mechanical force. It plays a fundamental role in essential cellular processes, including cytokinesis, cell migration, polarization, adhesion, maintenance of cell shape, and intracellular transport. NMHC IIA is widely expressed in various tissues and is particularly critical for platelet formation and function, as well as renal podocyte integrity. Mutations in the MYH9 gene lead to a group of autosomal dominant disorders collectively known as MYH9-related diseases (MYH9-RD), characterized by macrothrombocytopenia, sensorineural hearing loss, cataracts, and progressive glomerulonephritis.
In oncology, MYH9 is frequently overexpressed in multiple cancers (such as breast, lung, gastric, and esophageal cancers) and is associated with tumor invasion, metastasis, epithelial-to-mesenchymal transition (EMT), and resistance to chemotherapies. It also acts as a host cell receptor or entry mediator for several viruses, including herpes simplex virus 1 (HSV-1). Pharmacological targeting of MYH9 primarily involves small-molecule inhibitors like blebbistatin, which directly block its ATPase activity and disrupt actomyosin contractility. Other therapeutic strategies focus on modulating MYH9 expression or its upstream regulatory pathways (such as ROCK or PI3K/AKT/mTOR) to suppress cancer progression and metastasis.
Direct inhibition of the ATPase activity of the myosin motor domain, preventing actin-myosin interaction and actomyosin contractility; indirect modulation of expression or phosphorylation levels to affect downstream signaling pathways such as PI3K/AKT/mTOR and beta-catenin.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-muscle myosin heavy chain IIA (MYH9).